Beroni Group Announced the Latest Clinical Study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method)
August 31, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced the latest clinical...
Global COVID-19 Diagnostics Market Predicted to Garner Noteworthy Revenue of $65,750.1 Million by 2028 at a CAGR of 3.5% from 2021-2028 – Exclusive Report [410 Pages] By Research Dive
July 20, 2021 09:04 ET
|
Research Dive
New York, USA, July 20, 2021 (GLOBE NEWSWIRE) -- A recently published report by Research Dive states that the global COVID-19 diagnostics market is expected to observe an increase in revenue from...
Gennao Bio Appoints Chris Duke as Chief Operating Officer and Julie Hambleton, M.D., to Board of Directors
July 13, 2021 07:30 ET
|
Gennao Bio
HOPEWELL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the...
OncoResponse Appoints Sean McCarthy to Board of Directors
July 07, 2021 07:00 ET
|
OncoResponse, Inc.
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to...
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
June 28, 2021 08:30 ET
|
Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...
Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual Meeting
April 10, 2021 08:30 ET
|
Gennao Bio
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver...
Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
April 05, 2021 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Teracero Pharma annonce avoir reçu la première autorisation au Canada en vertu de l'arrêté d’urgence du ministre de la Santé pour un test sérologique rapide pour la COVID-19
March 17, 2021 14:00 ET
|
Teracero Pharma Inc.
Le test NADAL COVID-19 IgG/IgM de nal von Minden GmbH est très sensible et spécifique aux anticorps contre le SRAS-CoV-2, ne nécessite aucune formation particulière et fournit des résultats en 10...
A new stage in COVID-19 testing – Teracero Pharma reports receiving the first authorization for a COVID-19 serology rapid test under the Minister of Health’s Interim Order
March 17, 2021 14:00 ET
|
Teracero Pharma Inc.
nal von Minden GmbH’s NADAL COVID-19 IgG/IgM Test is highly sensitive and specific to antibodies against SARS-CoV-2, requires no special training, and can provide results within 10 minutes MONTREAL,...
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 11, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...